Dallan Murray's most recent trade in Sarepta Therapeutics Inc was a trade of 16,644 Stock Options (right to buy) done . Disclosure was reported to the exchange on March 7, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 16,644 | 16,644 | - | - | Stock Options (right to buy) | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 8,276 | 38,202 (0%) | 0% | - | Common Stock | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 5,500 | 33,659 (0%) | 0% | - | Common Stock | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 5,500 | 0 | - | - | Performance Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.13 per share. | 07 Mar 2025 | 2,737 | 29,926 (0%) | 0% | 100.1 | 274,056 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 100.13 per share. | 07 Mar 2025 | 996 | 32,663 (0%) | 0% | 100.1 | 99,729 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,500 | 0 | - | - | Performance Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2025 | 17,500 | 37,321 (0%) | 0% | - | Common Stock | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.70 per share. | 06 Mar 2025 | 8,613 | 28,159 (0%) | 0% | 103.7 | 893,168 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.70 per share. | 06 Mar 2025 | 549 | 36,772 (0%) | 0% | 103.7 | 56,931 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.34 per share. | 04 Mar 2025 | 1,685 | 19,821 (0%) | 0% | 101.3 | 170,758 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 103.77 per share. | 03 Mar 2025 | 711 | 21,506 (0%) | 0% | 103.8 | 73,780 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 3,500 | 17,500 | - | - | Performance Restricted Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 24,375 (0%) | 0% | - | Common Stock | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 6,250 | - | - | Performance Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2024 | 6,250 | 0 | - | - | Performance Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 5,500 | 5,500 | - | - | Performance Stock Units | |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 164.64 per share. | 21 Jun 2024 | 2,352 | 22,023 (0%) | 0% | 164.6 | 387,233 | Common Stock |
Sarepta Therapeutics Inc | Dallan Murray | Chief Customer Officer | Sale of securities on an exchange or to another person at price $ 140.00 per share. | 02 May 2024 | 3,635 | 18,125 (0%) | 0% | 140 | 508,900 | Common Stock |